Free Trial

Knowles (NYSE:KN) Issues Q2 2024 Earnings Guidance

Knowles (NYSE:KN - Get Free Report) updated its second quarter 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.220-0.260 for the period, compared to the consensus EPS estimate of 0.230. The company issued revenue guidance of $199.0 million-$209.0 million, compared to the consensus revenue estimate of $205.5 million. Knowles also updated its Q2 guidance to $0.22 to $0.26 EPS.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. StockNews.com raised Knowles from a hold rating to a buy rating in a research report on Friday, February 16th. TheStreet raised Knowles from a d+ rating to a c- rating in a research note on Tuesday, January 2nd.

Get Our Latest Stock Analysis on KN

Knowles Stock Down 0.2 %

Shares of NYSE KN traded down $0.04 during mid-day trading on Wednesday, reaching $15.80. 573,463 shares of the company traded hands, compared to its average volume of 515,523. The stock has a market cap of $1.42 billion, a PE ratio of 20.05 and a beta of 1.49. The company's fifty day moving average is $15.95 and its two-hundred day moving average is $16.08. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.41 and a current ratio of 2.61. Knowles has a fifty-two week low of $12.78 and a fifty-two week high of $18.48.


Knowles (NYSE:KN - Get Free Report) last posted its earnings results on Wednesday, February 7th. The communications equipment provider reported $0.22 EPS for the quarter, topping the consensus estimate of $0.19 by $0.03. The business had revenue of $215.20 million during the quarter. Knowles had a return on equity of 5.28% and a net margin of 10.23%.

Insiders Place Their Bets

In related news, SVP Raymond D. Cabrera sold 10,300 shares of the business's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $16.90, for a total value of $174,070.00. Following the completion of the sale, the senior vice president now directly owns 94,870 shares in the company, valued at approximately $1,603,303. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.57% of the company's stock.

About Knowles

(Get Free Report)

Knowles Corporation offers capacitors, radio frequency (RF) filtering products, balanced armature speakers, micro-acoustic microphones, and audio solutions in Asia, the United States, Europe, other Americas, and internationally. It operates through three segments: Precision Devices (PD); Medtech & Specialty Audio (MSA); and Consumer MEMS Microphones (CMM).

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Knowles right now?

Before you consider Knowles, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knowles wasn't on the list.

While Knowles currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Featured Articles and Offers

Biotech Boom: Stocks Skyrocketing & What's Next

Biotech Boom: Stocks Skyrocketing & What's Next

Dive into biotech's latest trends with Dylan Jovine: weight loss breakthroughs, smart chemo innovations, and expert stock evaluation tips.

Search Headlines: